Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Early Toxicity Testing Market by Technique (In vivo, In vitro, and In silico), End Users (Pharmaceuticals Industry, Diagnostics Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Other Industries) - Global Opportunity Analysis and Industry Forecast, 2014-2022

LI_17619
Pages: 220
May 2017 | 1948 Views
face gplus_n
Author's : Onkar Sumant
Tables: 63
Charts: 66
twit_n pr_n

Early Toxicity Testing Market Overview:

Global Early Toxicity Testing Market was $614 million and is estimated to reach $1,012 million by 2022, registering a CAGR of 7.3% from 2016 to 2022. Toxins are substances that can adversely affect living organisms. They are present in a variety of products such as food additives, chemicals, pesticides, and cosmetics. During drug development, it was observed that approximately 26% of the products face rejection in the later stages of development due to safety issues. This leads to massive financial losses for many industries, which include pharmaceuticals and food industries. To avoid the financial losses, early toxicity tests are used to remove the toxic component in the product and reduce the risk of late-stage failure. Different types of toxic tests such as acute toxicity tests, neurotoxicity, systemic toxicity, and carcinogenicity are conducted using in vivo and in vitro techniques. These toxicity tests help the companies provide proofs to the regulatory bodies that they are safe for humans and will not adversely affect human health.

Early Toxicity Testing Market

The global early toxicity testing market is segmented based on technique, end users, and geography. Based on technique, the market is categorized into in vivo, in vitro, and in silico. Based on the type of assay used, in vitro technique is further divided into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA and western blots, tissues culture assays, receptor binding assays, and other assays. Based on the toxicity end-points, in vitro technique is further segmented into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, genotoxicity, neurotoxicity, organ toxicity, and other toxicity endpoints. Based on end-users, the market is segmented into pharmaceuticals industry, diagnostics industry, food industry, chemicals industry, cosmetics industry, and other industries. The market is analyzed based on four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

Early Toxicity Testing Market

The market is expected to witness moderate growth during the forecast period, owing to the increase in awareness of the regulatory authorities concerning environment and public health welfare. In addition, replacement of in vivo models with in vitro models and technological advancement in the in vitro and in vivo technique supplement the market growth. As early toxicity tests can help reduce the risk of drug failure in later stages, there is a rise in the demand for early toxicity tests. This has increased investment in the R&D for these products, which help boost the market growth. However, limited awareness about the benefits of early toxicity testing and limitations of preclinical testing are expected to hamper the market growth.

Early Toxicity Testing Market

The early toxicity testing market is growing at a steady pace due to the increase in stringency of regulatory authorities regarding environment and public welfare. Furthermore, the use of early toxicity tests reduce the risks of drug failure in later stages of drug development, thus preventing heavy financial losses of the companies. This has led to the growth in the investment for R&D of toxicity testing techniques and emergence of new models & tests to evaluate the toxicity of the substance. For instance, on July 2016, Cyprotex PLC launched an in vitro 3D cellular model that could be used to evaluate cardiotoxicity.

The key players profiled in this report include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Agilent Technologies Inc., Quest Diagnostics Incorporation, Merck & Co., Inc., Charles River Laboratories International Incorporation, Becton, Dickinson And Company, Danaher Corporation, Evotec Ag, and The Jackson Laboratory.

There are other players in the early toxicity testing market which include Covance, CellSystems, BioQuanta, Epithelix, Celther Polska, and HemoGenix

Asia-Pacific possesses high market potential for growth of early toxicity testing due to increase in demand for toxicity tests and upsurge in governmental initiatives to protect public health and environment. Progress in the research of in vitro and in silico technique has led to rapid developments in the toxicity testing products.

Early toxicity testing market in India is projected to grow at a high CAGR of 13.2% during the forecast period. Asia-Pacific is experiencing fast-paced growth in terms of production and development of early toxicity testing products.

Key Benefits

  • This report entails detailed quantitative analysis of the current market trends for the period of 2014-2022 to identify the prevailing opportunities.
  • The market estimations provided in the report are based on comprehensive analysis of the key developments in the industry.
  • The global early toxicity testing market is comprehensively analyzed with respect to technique, end users, and geography.
  • In-depth analysis based on geography helps understand the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

Early Toxicity Testing Market Key Segments

The global early toxicity testing market segmentation is explained below:

By Technique

  • In vivo
  • In vitro

By Assay

  • Enzyme Toxicity Assays
  • Bacterial Toxicity Assays
  • Cell-Based ELISA and Western Blots
  • Tissues Culture Assays
  • Receptor Binding Assays
  • Other Assays

By Toxicity End-points

  • Dermal Toxicity
  • Systemic Toxicity
  • Carcinogenicity
  • Ocular Toxicity
  • Skin Sensitization and Irritation
  • Genotoxicity
  • Neurotoxicity
  • Organ Toxicity
  • Other Toxicity Endpoints and Tests
  • In silico

By End Users

  • Pharmaceuticals industry
  • Diagnostics industry
  • Food industry
  • Chemicals industry
  • Cosmetics industry
  • Other industries

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1.1. CXO perspective

Chapter: 3 MARKET OVERVIEW

3.1. REPORT DESCRIPTION
3.2. KEY BENEFITS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PATENT ANALYSIS

3.3.1. Patent analysis by year
3.3.2. Patent analysis by region

3.4. GOVERNMENT REGULATIONS
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increased stringency of regulatory authorities concerning environment welfare
3.5.1.2. Replacement of in vivo models by in vitro model
3.5.1.3. Increased stringency of regulatory authorities concerning public health welfare
3.5.1.4. Adoption of early toxicity in order to reduce drug failure in later stages

3.5.2. Restrains

3.5.2.1. Limited awareness about the benefits of early toxicity testing
3.5.2.2. Limitation of preclinical testing

3.5.3. Opportunities

3.5.3.1. Advancement in in silico platforms
3.5.3.2. Advancement in in vitro models

Chapter: 4 GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. IN VIVO

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. IN VITRO

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. In vitro toxicity testing market by assays

4.3.4.1. Enzyme toxicity assays

4.3.4.1.1. Market size and forecast

4.3.4.2. Bacterial toxicity assays

4.3.4.2.1. Market size and forecast

4.3.4.3. Cell-based ELISA and western blots

4.3.4.3.1. Market size and forecast

4.3.4.4. Tissue culture assays

4.3.4.4.1. Market size and forecast

4.3.4.5. Receptor binding assays

4.3.4.5.1. Market size and forecast

4.3.4.6. Other assays

4.3.4.6.1. Market size and forecast

4.3.5. In vitro toxicity testing market by toxicity end-points

4.3.5.1. Dermal toxicity

4.3.5.1.1. Market size and forecast

4.3.5.2. Systemic toxicity

4.3.5.2.1. Market size and forecast

4.3.5.3. Carcinogenicity

4.3.5.3.1. Market size and forecast

4.3.5.4. Ocular toxicity

4.3.5.4.1. Market size and forecast

4.3.5.5. Skin sensitization and irritation

4.3.5.5.1. Market size and forecast

4.3.5.6. Genotoxicity

4.3.5.6.1. Market size and forecast

4.3.5.7. Neurotoxicity

4.3.5.7.1. Market size and forecast

4.3.5.8. Organ toxicity

4.3.5.8.1. Market size and forecast

4.3.5.9. Other toxicity endpoints

4.3.5.9.1. Market size and forecast

4.4. IN SILICO

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 EARLY TOXICITY TESTING MARKET, BY END USERS

5.1. OVERVIEW

5.1.1. Key market trends
5.1.2. Key growth factors and opportunities
5.1.3. Market size and forecast

5.2. PHARMACEUTICAL INDUSTRY

5.2.1. Market size and forecast

5.3. DIAGNOSTICS INDUSTRY

5.3.1. Market size and forecast

5.4. FOOD INDUSTRY

5.4.1. Market size and forecast

5.5. CHEMICALS INDUSTRY

5.5.1. Market size and forecast

5.6. COSMETICS INDUSTRY

5.6.1. Market size and forecast

5.7. OTHER INDUSTRY

5.7.1. Market size and forecast

Chapter: 6 EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size & forecast
6.2.5. Canada market size & forecast
6.2.6. Mexico market size & forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany market size & forecast
6.3.5. France market size & forecast
6.3.6. U.K. market size & forecast
6.3.7. Rest of Europe market size & forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan market size & forecast
6.4.5. China market size & forecast
6.4.6. Australia market size & forecast
6.4.7. India market size & forecast
6.4.8. Rest of Asia Pacific market size & forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size & forecast
6.5.5. Republic of South Africa market size & forecast
6.5.6. Rest of LAMEA market size & forecast

Chapter: 7 COMPANY PROFILES

7.1. THERMO FISHER SCIENTIFIC INC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. BIO-RAD LABORATORIES, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. AGILENT TECHNOLOGIES INC.

7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Business performance

7.4. QUEST DIAGNOSTICS INCORPORATION

7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Product portfolio
7.4.4. Business performance

7.5. MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Product portfolio
7.5.4. Business performance
7.5.5. Key strategic moves & developments, 2014-2016

7.6. CHARLES RIVER LABORATORIES INTERNATIONAL INCORPORATION

7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance
7.6.5. Key strategic moves & developments, 2014-2016

7.7. BECTON, DICKINSON AND COMPANY

7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Product portfolio
7.7.4. Business performance

7.8. DANAHER CORPORATION

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. EVOTEC AG

7.9.1. Company overview
7.9.2. Operating business segments
7.9.3. Product portfolio
7.9.4. Business performance
7.9.5. Key strategic moves & developments, 2014-2016

7.10. THE JACKSON LABORATORY

7.10.1. Company overview
7.10.2. Product portfolio
7.10.3. Business performance
7.10.4. Key strategic moves & developments, 2014-2016

LIST OF TABLES

TABLE 1. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 2. GLOBAL IN VIVO EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 3. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 4. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 5. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 6. GLOBAL IN SILICO EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 7. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 8. GLOBAL EARLY TOXICITY TESTING PHARMACEUTICAL INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 9. GLOBAL EARLY TOXICITY TESTING DIAGNOSTICS INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 10. GLOBAL EARLY TOXICITY TESTING FOOD INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 11. GLOBAL EARLY TOXICITY TESTING CHEMICAL INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 12. GLOBAL EARLY TOXICITY TESTING COSMETICS INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 13. GLOBAL EARLY TOXICITY TESTING PHARMACEUTICAL INDUSTRY MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 14. GLOBAL EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 15. GLOBAL NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 16. GLOBAL NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 17. GLOBAL NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 18. GLOBAL NORTH AMERICA IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 19. GLOBAL NORTH AMERICA IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 20. GLOBAL EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 21. GLOBAL EUROPE EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 22. GLOBAL EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 23. GLOBAL EUROPE IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 24. GLOBAL EUROPE IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 25. GLOBAL ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 26. GLOBAL ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 27. GLOBAL ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 28. GLOBAL ASIA-PACIFIC IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 29. GLOBAL ASIA-PACIFIC IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 30. GLOBAL LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE 2014-2022 ($MILLION)
TABLE 31. GLOBAL LAMEA EARLY TOXICITY TESTING MARKET, BY END USERS 2014-2022 ($MILLION)
TABLE 32. GLOBAL LAMEA EARLY TOXICITY TESTING MARKET, BY COUNTRY 2014-2022 ($MILLION)
TABLE 33. GLOBAL LAMEA IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAY 2014-2022 ($MILLION)
TABLE 34. GLOBAL LAMEA IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINTS 2014-2022 ($MILLION)
TABLE 35. THERMO FISHER: COMPANY SNAPSHOT
TABLE 36. THERMO FISHER: OPERATING SEGMENTS
TABLE 37. THERMO FISHER: PRODUCT PORTFOLIO
TABLE 38. BIO-RAD: COMPANY SNAPSHOT
TABLE 39. BIO-RAD: OPERATING SEGMENTS
TABLE 40. BIO-RAD: PRODUCT PORTFOLIO
TABLE 41. AGILENT: COMPANY SNAPSHOT
TABLE 42. AGILENT: OPERATING SEGMENTS
TABLE 43. AGILENT: PRODUCT PORTFOLIO
TABLE 44. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 45. QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 46. QUEST DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 47. MERCK: COMPANY SNAPSHOT
TABLE 48. MERCK: OPERATING SEGMENTS
TABLE 49. MERCK: PRODUCT PORTFOLIO
TABLE 50. CHARLES RIVER: COMPANY SNAPSHOT
TABLE 51. CHARLES RIVER: OPERATING SEGMENTS
TABLE 52. CHARLES RIVER: PRODUCT PORTFOLIO
TABLE 53. BD: COMPANY SNAPSHOT
TABLE 54. BD: OPERATING SEGMENTS
TABLE 55. BD: PRODUCT PORTFOLIO
TABLE 56. DANAHER: COMPANY SNAPSHOT
TABLE 57. DANAHER: OPERATING SEGMENTS
TABLE 58. DANAHER: PRODUCT PORTFOLIO
TABLE 59. EVOTEC: COMPANY SNAPSHOT
TABLE 60. EVOTEC: OPERATING SEGMENTS
TABLE 61. EVOTEC: PRODUCT PORTFOLIO
TABLE 62. JAX: COMPANY SNAPSHOT
TABLE 63. JAX: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL EARLY TOXICITY TESTING MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL EARLY TOXICITY TESTING MARKET, BY END USERS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. PATENT REGISTERED/APPROVED- BY YEAR
FIGURE 5. PATENT REGISTERED/APPROVED- BY REGION
FIGURE 6. ENZYME TOXICITY ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 7. BACTERIAL TOXICITY ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 8. CELL-BASED ELISA AND WESTERN BLOTS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 9. TISSUE CULTURE ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 10. RECEPTOR BINDING ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 11. OTHER IN VITRO ASSAYS FOR EARLY TOXICITY TESTING MARKET, 2014-2022($MILLION)
FIGURE 12. DERMAL TOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022
FIGURE 13. SYSTEMIC TOXICITY TESTS FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 14. CARCINOGENICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 15. OCULAR TOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 16. SKIN SENSITIZATION AND IRRITATION FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 17. GENOTOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 18. NEUROTOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 19. ORGAN TOXICITY FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 20. OTHER TOXICITY ENDPOINTS FOR EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 21. U.S. EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 22. CANADA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 23. MEXICO EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 24. GERMANY EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 25. FRANCE EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 26. U.K. EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 27. REST OF EUROPE EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 28. JAPAN EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 29. CHINA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 30. AUSTRALIA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 31. INDIA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 32. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 33. BRAZIL EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 34. REPUBLIC OF SOUTH AFRICA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 35. REST OF LAMEA EARLY TOXICITY TESTING MARKET, 2014-2022 ($MILLION)
FIGURE 36. THERMO FISHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 37. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 38. THERMO FISHER: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 39. BIO-RAD: REVENUE, 2014-2016 ($MILLION)
FIGURE 40. BIO-RAD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. BIO-RAD: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 42. AGILENT: REVENUE, 2014-2016
FIGURE 43. AGILENT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 44. AGILENT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 45. QUEST: REVENUE, 2014-2016 ($MILLION)
FIGURE 46. AGILENT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 47. MERCK: REVENUE, 2014-2016 ($MILLION)
FIGURE 48. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 49. MERCK: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 50. MERCK: STRATEGY SHARE, 2014-2016 (%)
FIGURE 51. CHARLES RIVER: REVENUE, 2014-2016 ($MILLION)
FIGURE 52. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 53. CHARLES RIVER: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 54. CHARLES RIVER: STRATEGY SHARE, 2014-2016 (%)
FIGURE 55. BD: REVENUE, 2014-2016 ($MILLION)
FIGURE 56. BD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 57. BD: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 58. DANAHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 59. DANAHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 60. DANAHER: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 61. EVOTEC: REVENUE, 2013-2015 ($MILLION)
FIGURE 62. EVOTEC: REVENUE SHARE BY SEGMENT, 2015 (%)
FIGURE 63. EVOTEC: REVENUE SHARE, BY GEOGRAPHY, 2015 (%)
FIGURE 64. EVOTEC: STRATEGY SHARE, 2014-2016 (%)
FIGURE 65. JAX: REVENUE, 2013-2015 ($MILLION)
FIGURE 66. JAX: STRATEGY SHARE, 2014-2016 (%)

 

There has been a rise in number of drug failures in the later stages of drug testing. These stages are very expensive to perform and later stage drug failure causes heavy financial losses to the company. In many cases issues related to the safety of the product is the reason for such drug failures. During preclinical trials, different toxicity tests can assess the adverse effects of the product and can help reduce the risk of later stage failure during drug development. Hence, the companies prefer to perform more toxicity tests at early stages to prevent the toxicity related failures in the later stages and thus reduce the risk of financial losses due to later stage failure. Although early toxicity testing is mostly used to check the toxicity levels of the test drug during drug development, recent trends of toxicity testing for cosmetic products also drive the growth in the early toxicity testing market. Increase in the emergence of new compounds used for food additives and new materials used for packaging purposes fuel the growth of the segment. Increase in stringency of government regulators for the environment and human health welfare also boost the market growth.

The in vivo technique is banned in many countries due to the opposition of many organizations of animal rights. This has led to an increase in the demand of in vitro and in silico techniques for toxicity testing, which has increased the R&D for these products. Many key players work toward developing in vitro and in silico products that are safe and effective. As in silico technique is still in its developmental stage, there is a scope of advancement in the technology, which will help increase the revenue generated by the market. Furthermore, the food industry is also one of the key end users of early toxicity testing market.

The employment of technologically advanced products is highest in Europe, owing of the increase in adoption of these products and presence of disposable income among the owners. The rise in the disposable income, demand for toxicity tests in the developing countries such as China and India, and adoption of in vitro and in silico techniques for toxicity testing largely contribute toward the market growth in the Asia-Pacific region, making it the fastest growing region.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Early Toxicity Testing Market- Global Opportunity Analysis and Industry Forecast, 2014-2022

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts